Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT) that may be made worse by surgery. TGCT is a condition where tumors form in joints of the ...

Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...

Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...

Tenosynovial giant cell tumors are not malignant but can impact patients’ quality of life, as one expert explained. There are not many patients with tenosynovial giant cell tumors, or TGCTs, with one ...

Dissociated Tumor Cells (DTCs) are single-cell suspensions dissociated from a solid tumor through the use of digestive enzymes and mechanical separation. This has the benefit of cryopreserving the ...

The study explored the complex interactions between tumor cells and immune cells, including T cells, M1/M2 macrophages, and their localized impact on the tumor microenvironment, offering insights that ...

Craniopharyngiomas are brain tumors that negatively impact the hormonal function of the nearby pituitary. The tumor location often prevents necessary surgical intervention. Alternative pharmacological ...